BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Pulmonary arterial hypertension clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for pulmonary arterial hypertension: 94 (53 sponsors; 19 newly posted in the last 180 days, 7 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 21.3, rank 24 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 3, Phase 2 26, Phase 3 26, Phase 4 5, N/A 34.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Insmed Incorporated INSM4P3 401
Liquidia Technologies, Inc. LQDA5P3 3, P4 1, NA 111
Actelion4P3 3, P2 101
Tenax Therapeutics, Inc. TENX3P3 300
Merck Sharp & Dohme LLC MRK9P2 5, P4 2, P3 240
United Therapeutics UTHR6P3 2, P2 1, NA 2, P4 122
Inhibikase Therapeutics IKT2P3 210
AOP Orphan Pharmaceuticals AG4NA 2, P4 1, P3 110
Pulmovant, Inc.3P2 2, P3 111
Pulnovo Medical (Wuxi) Co., Ltd.2P3 1, NA 100
Bayer1P3 100
Gossamer Bio USA, Inc. GOSS1P3 101
TransThera Sciences (Nanjing), Inc.1P3 100
VIVUS LLC new entrant1P3 110
Eko Devices, Inc.3NA 300
Gradient Denervation Technologies3NA 300
Novlead Inc.3NA 310
35Pharma Inc., a GSK company2P2 200
IRulya Therapeutics Inc. IRLA2P2 210
NS Pharma, Inc.2P2 200
Abbott Medical Devices1NA 100
Aether Tech S.L. ATHR new entrant1NA 111
AllRock Bio, Inc.1P2 101
Apollo Therapeutics Ltd APO1P2 100
Aria CV, Inc1NA 100

New-entrant sponsors: VIVUS LLC, Aether Tech S.L..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-24 est.P2Tectonic Therapeutic TECXNCT06616974 A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)Pulmonary Hypertension; Heart Failure With Preserved Ejection Fractionactive not recruiting191
2026-12 est.P3United Therapeutics UTHRNCT03683186 A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension; Hypertension; Connective Tissue Diseasenrolling by invitation1000
2026-12 est.P3Gossamer Bio USA, Inc. GOSSNCT06274801 Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Pulmonary Arterial Hypertensionrecruiting330
2026-12 est.P2Pulmovant, Inc.NCT07333183 A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILDPulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases; Vascular Diseases; Cardiovasrecruiting20
2026-12-31 est.P2/P3Insmed Incorporated INSMNCT05649748 An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertensionactive not recruiting91

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-09P2Pfizer PFENCT07073820 A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical StuPulmonary Hypertensionterminated42
2026-09-09P2Gossamer Bio USA, Inc. GOSSNCT04816604 Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertensionterminated74
2026-07-31P1/P2Pfizer PFENCT06137742 A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensioncompleted97
2026-06-30P3Tenax Therapeutics, Inc. TENXNCT05983250 LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFPulmonary Hypertensionactive not recruiting230
2026-05-26P2Pulmovant, Inc.NCT06635850 A Study of Mosliciguat in PH-ILDPulmonary Hypertension; Interstitial Lung Disease; Lung Diseases; Vascular Diseases; Cardiovascular active not recruiting135

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "pulmonary arterial hypertension"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.